Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Pre-Interphex 2010 Product Releases.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 83-87

CHEMICALS, RAW MATERIALS, INTERMEDIATES, & EXCIPIENTS



High-purity inorganic salts
Jost manufactures high-purity ammonium sulfate in several grades, and the company also provides sodium phosphate and dodecahydrate. These inorganic salts are appropriate as biological buffers and as process intermediates for synthesizing active pharmaceutical ingredients. Jost manufactures more than 250 chemical salts in a facility registered with the US Food and Drug Administration. Jost Chemical, St. Louis, MO http://www.jostchemical.com/ tel. 314.428.4300



Excipient
The PanExcea MC200G performance excipient for oral disintegrating tablet applications combines two ingredients for rapid tablet disintegration and dispersion with good taste and texture. Designed for flexibility, PanExcea MC200G performance excipient enables high active-ingredient loading capacity and reduces tableting, licensing, and equipment expenses. Mallinckrodt Baker, Phillipsburg NJ http://www.mallbaker.com/ tel. 800.943.4747



Website
Roquette has launched a website for its pharmaceutical division. The site grants access to the company's excipient and active product lines and offers information about services. A formulation tool provides assistance to formulators from the product development cycle through to launch. The special services and support sections describe Roquette's application expertise. Roquette, Keokuk, IA http://www.roquette-pharma.com/ tel. 319-524-5757


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here